Process and compounds for the manufacture of oseltamivir and analogs thereof, and new antiviral agents
AssigneeBrock University
InventorsTomas Hudlicky, Lukas Werner, Ales Machara
Life of this patent
Estimating the term…
Abstract
The present application relates to processes for the preparation of intermediates useful in the manufacture of oseltamivir and the H3PO4 salt of oseltamivir, Tamiflu®. The application further relates to novel intermediate and compounds and oseltamivir analogs and to pharmaceutical compositions comprising said analog compounds. The application further relates to a method of using the novel analogs of oseltamivir to treat or prevent influenza.
Claims65
A process for the preparation of a compound of formula I:
- wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
- R2 and R3 are independently, suitable protecting groups, or R2 and R3 are joined to form a suitable protecting group;
- R4a and R4b are independently selected from H and a suitable protecting group or R4a and
- R4b are joined to form a suitable protecting group;
- R5a and R5b are independently selected from H and a suitable protecting group or R5a and
- R5b are joined to form a suitable protecting group;
- the process comprising:
- (i) treating a compound of the formula II, wherein R1, R2, R3, R4a and R4b are as defined in formula I under conditions for the [3,3] oxidative rearrangement of the allylic alcohol to provide a compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I,
- (ii) converting the compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I, to a compound of the formula IV, wherein R1, R2, R3, R4a and R4b are as defined in formula I and R7 is a group that is removed under reduction or hydrogenation reaction conditions or R7 is a suitable acid labile protecting group,
- and
- (iii) reducing or hydrogenating the compound of the formula IV, optionally in the presence of a suitable protecting group reagent, to provide compounds of the formula I, wherein:
- a) R5a and R5b are H when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is not present;
- b) one of R5a and R5b is H and the other is a suitable protecting group or R5a and R5b are joined to form a suitable protecting group when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is present;
- or
- c) one of R5a and R5b is H and the other is a suitable acid labile protecting group when R7 is a suitable acid labile protecting group,
- wherein, in the compounds of the formulae I, II, III and/or IV, one or more available hydrogens in R1, R2, R3, R4a, R4b, R5a, R5b and/or R7 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formulae I, II, III and/or IV is/are optionally replaced with an isotopic label.
A process for the preparation of a compound of formula I:
- wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
- R2 and R3 are independently, suitable protecting groups, or R2 and R3 are joined to form a suitable protecting group;
- R4a and R4b are independently selected from H and a suitable protecting group or R4a and R4b are joined to form a suitable protecting group;
- R5a and R5b are independently selected from H and a suitable protecting group or R5a and R5b are joined to form a suitable protecting group;
- the process comprising:
- (i) treating a compound of the formula II, wherein R1, R2, R3, R4a and R4b are as defined in formula I under conditions for the [3,3] oxidative rearrangement of the allylic alcohol to provide a compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I,
- (ii) converting the compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I, to a compound of the formula IV, wherein R1, R2, R3, R4a and R4b are as defined in formula I and R7 is a group that is removed under reduction or hydrogenation reaction conditions or R7 is a suitable acid labile protecting group,
- and
- (iii) reducing or hydrogenating the compound of the formula IV, optionally in the presence of a suitable protecting group reagent, to provide compounds of the formula I, wherein:
- a) R5a and R5b are H when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is not present;
- b) one of R5a and R5b is H and the other is a suitable protecting group or R5a and R5b are joined to form a suitable protecting group when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is present;
- or
- c) one of R5a and R5b is H and the other is a suitable acid labile protecting group when R7 is a suitable acid labile protecting group,
- wherein, in the compounds of the formulae I, II, III and/or IV, one or more available hydrogens in R1, R2, R3, R4a, R4b, R5a, R5b and/or R7 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formulae I, II, III and/or IV is/are optionally replaced with an isotopic label.
A compound of the formula III:
- wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
- R2 and R3 are independently selected from H and a suitable protecting group, or R2 and
- R3 are joined to form a suitable protecting group;
- and
- R4a and R4b are independently selected from H and a suitable protecting group or R4a and
- R4b are joined to form a suitable protecting group;
- wherein, one or more available hydrogens in R1, R2, R3, R4a and/or R4b is/are optionally replaced with F and/or one or more of available atoms is/are optionally replaced with an isotopic label,
- or a salt and/or solvate thereof.
A compound of the formula IV:
- wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
- R2 and R3 are independently selected from H and a suitable protecting group, or R2 and
- R3 are joined to form a suitable protecting group;
- R4a and R4b are independently selected from H and a suitable protecting group or R4a and
- R4b are joined to form a suitable protecting group;
- and
- R7 is a group that is removed under reduction or hydrogenation reaction conditions or R7 is a suitable acid labile protecting group,
- wherein, one or more available hydrogens in R1, R2, R3, R4a, R4b and/or R7 is/are optionally replaced with F and/or one or more of available atoms is/are optionally replaced with an isotopic label,
- or a salt, solvate and/or prodrug thereof.
A compound of formula V:
- wherein
- R10 and R11 are independently selected from H, C1-6alkyl and C1-6acyl, or R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-6alkyl;
- R12a and R12b are independently selected from H, C1-6alkyl and C1-6acyl;
- R13 is selected from OR14 and NR15aR15b or R13 is ═O or ═NR16;
- R14 is selected from H, C1-6alkyl and C1-6acyl;
- R15a and R15b are independently selected from H, C1-6alkyl and C1-6acyl;
- R16 is selected from H, OH, C1-6alkyl, OC1-6alkyl, C1-6acyl, OC1-6acyl, NH2, NHC1-6alkyl, N(C1-6alkyl)(C1-6alkyl) and NHC1-6acyl, or
- R16 and one of R12a and R12b form a linker group “-A-C(O)-” to provide a compound of the formula:
- wherein A is O or NH;
- X+ is a cation;
- and
- one or more available hydrogens in R10, R11, R12a, R12b, R13, R14, R15a, R15b and/or R16 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
- or a pharmaceutically acceptable salt, and/or solvate thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound of the formula VI:
- wherein
- R16 and R17 are independently selected from H, C1-6alkyl and C1-6acyl, or R16 and R17 are joined together to form, together with the atoms to which they are attached, a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl;
- R18a and R18b are independently selected from H, C1-6alkyl and C1-6acyl;
- R19 is selected from H, C1-6alkyl and C1-6acyl;
- Z+ is a cation;
- and
- one or more available hydrogens in R16, R17, R18a, R18b and/or R19 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
- or a pharmaceutically acceptable salt, and/or solvate thereof.
(canceled)
-52. (canceled)
(canceled)
(canceled)
-62. (canceled)
A method of treating or preventing influenza comprising administering an effective amount of one or more compounds of the formula V or VI:
- wherein
- R10 and R11 are independently selected from H, C1-6alkyl and C1-6 acyl, or R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-6alkyl;
- R12a and R12b are independently selected from H, C1-6alkyl and C1-6acyl;
- R13 is selected from OR14 and NR15aR15b or R13 is ═O or ═NR16;
- R14 is selected from H, C1-6alkyl and C1-6acyl;
- R15a and R15b are independently selected from H, C1-6alkyl and C1-6acyl;
- R16 is selected from H, OH, C1-6alkyl, OC1-6alkyl, C1-6acyl, OC1-6acyl, NH2, NHC1-6alkyl, N(C1-6alkyl)(C1-6alkyl) and NHC1-6acyl, or
- R16 and one of R12a and R12b form a linker group “-A-C(O)-” to provide a compound of the formula:
- wherein A is O or NH;
- X+ is a cation;
- and
- one or more available hydrogens in R10, R11, R12a, R12b, R13, R14, R15a, R15b and/or R16 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
- or a pharmaceutically acceptable salt, and/or solvate thereof;
- or
- wherein
- R16 and R17 are independently selected from H, C1-6alkyl and C1-6acyl, or R16 and R17 are joined together to form, together with the atoms to which they are attached, a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl;
- R18a and R18b are independently selected from H, C1-6alkyl and C1-6acyl;
- R19 is selected from H, C1-6alkyl and C1-6acyl;
- Z+ is a cation;
- and
- one or more available hydrogens in R16, R17, R18a, R18b and/or R19 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
- or a pharmaceutically acceptable salt, and/or solvate thereof, to a subject in need thereof.
A pharmaceutical composition comprising one or more compounds of the formula V or VI;
- wherein
- R10 and R11 are independently selected from H, C1-6alkyl and C1-6acyl, or R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-6alkyl;
- R12a and R12b are independently selected from H, C1-6alkyl and C1-6acyl;
- R13 is selected from OR14 and NR15aR15b or R13 is ═O or ═NR16;
- R14 is selected from H, C1-6alkyl and C1-6acyl;
- R15a and R15b are independently selected from H, C1-6alkyl and C1-6acyl;
- R16 is selected from H, OH, C1-6alkyl, OC1-6alkyl, C1-6acyl, OC1-6acyl, NH2, NHC1-6alkyl, N(C1-6alkyl)(C1-6alkyl) and NHC1-6acyl, or
- R16 and one of R12a and R12b form a linker group “-A-C(O)-” to provide a compound of the formula:
- wherein A is O or NH;
- X+ is a cation;
- and
- one or more available hydrogens in R10, R11, R12a, R12b, R13, R14, R15a, R15b and/or R16 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
- or a pharmaceutically acceptable salt, and/or solvate thereof;
- or
- wherein
- R16 and R17 are independently selected from H, C1-6alkyl and C1-6acyl, or R16 and R17 are joined together to form, together with the atoms to which they are attached, a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl;
- R18a and R18b are independently selected from H, C1-6alkyl and C1-6acyl;
- R19 is selected from H, C1-6alkyl and C1-6acyl;
- Z+ is a cation;
- and
- one or more available hydrogens in R16, R17, R18a, R18b and/or R19 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
- or a pharmaceutically acceptable salt, and/or solvate thereof,
- and a pharmaceutically acceptable carrier and/or diluent.
Dependencies are inferred from the claim text.